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Background.The extent of coronary artery calcium (CAC) improves cardiovascular disease (CVD) risk prediction.The association
between common dyslipidemias (combined hyperlipidemia, simple hypercholesterolemia, metabolic Syndrome (MetS), isolated
low high-density lipoprotein cholesterol, and isolated hypertriglyceridemia) compared with normolipidemia and the risk of
multivessel CAC is underinvestigated. Objectives. To determine whether there is an association between common dyslipidemias
compared with normolipidemia, and the extent of coronary artery involvement amongMESA participants who were free of clinical
cardiovascular disease at baseline. Methods. In a cross-sectional analysis, 4,917 MESA participants were classified into six groups
defined by specific LDL-c, HDL-c, or triglyceride cutoff points. Multivessel CAC was defined as involvement of at least 2 coronary
arteries. Multivariate Poisson regression analysis evaluated the association of each group with multivessel CAC after adjusting
for CVD risk factors. Results. Unadjusted analysis showed that all groups except hypertriglyceridemia had statistically significant
prevalence ratios of having multivessel CAC as compared to the normolipidemia group. The same groups maintained statistical
significance prevalence ratios with multivariate analysis adjusting for other risk factors including Agatston CAC score [combined
hyperlipidemia 1.41 (1.06–1.87), hypercholesterolemia 1.55 (1.26–1.92), MetS 1.28 (1.09–1.51), and low HDL-c 1.20 (1.02–1.40)].
Conclusion. Combined hyperlipidemia, simple hypercholesterolemia, MetS, and low HDL-c were associated with multivessel
coronary artery disease independent of CVD risk factors and CAC score. These findings may lay the groundwork for further
analysis of the underlying mechanisms in the observed relationship, as well as for the development of clinical strategies for primary
prevention.
1. Introduction
The total CAC score (Agatston score) using noncontrast com-
puted tomography is a recognized estimation of atheroscle-
rosis in asymptomatic adults with at least moderate risk of
cardiovascular disease [1–3]. When compared with a risk-
stratification tool such as the Framingham Risk Score (FRS),
the CAC score has been shown to have a superior role in
predicting future cardiac events and all-causemortality [2, 4].
Previous studies demonstrated that measurement of coro-
nary artery calcium stratified patient risk for cardiovascular
disease regardless of dyslipidemia burden or definition [5].
However, the relationship between subclinical atherosclerosis
and dyslipidemia type has been investigated using either the
prevalent CAC or carotid thickness as surrogate markers [5,
6]. Although the traditional AgatstonCAC score is a powerful
predictor of mortality, there is an emerging evidence that
extent of subclinical atherosclerosis, as indicated by the
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number of vessels withCAC, further improves cardiovascular
risk prediction [2, 7]. With the current ability to identify
those withmultivessel disease at an asymptomatic stage using
the CAC, the healthcare providers could potentially tailor the
diagnostic and therapeutic approach for individual patients
based on the extent of CAC. Therefore, the purpose of this
study was to determine whether there is an association be-
tween common dyslipidemias (combined hyperlipidemia,
simple hypercholesterolemia,MetS, isolated low high-density
lipoprotein cholesterol and isolated hypertriglyceridemia)
compared with normolipidemia, and the extent of coronary
artery involvement (multivessel CAC), among MESA par-
ticipants who were free of clinical cardiovascular disease at
baseline. It remains to be seen whether the association be-
tween dyslipidemia types and the CAD extent still exists after
controlling for the absolute calcium score.
2. Methods
2.1. Study Cohort. The Multiethnic Study of Atherosclerosis
(MESA) is a prospective observational evaluation of 6,814
men and women, aged 45 to 84 years, from four racial/ethnic
groups (White, Asian, Hispanic, and Black) in the United
States. At the time of enrollment, participants had no known
cardiovascular disease.
Participants were enrolled between July 2000 and
September 2002 at field centers located in Forsyth County,
NorthCarolina; St. Paul,Minnesota; Chicago;NewYorkCity;
Baltimore, Maryland; and Los Angeles. Institutional review
boards approved the study protocol at each study center.
Further details regarding the MESA study have been detailed
elsewhere [8].
Study participants provided information about cardio-
vascular risk factors. A central laboratory (University of
Vermont, Burlington, Vermont) measured levels of total and
high-density lipoprotein cholesterol, triglycerides, plasma
glucose, and high-sensitivity C-reactive protein (CRP) after
a 12-hour fast. The coronary calcium scan was done twice
in each participant to increase accuracy. For each scan, the
participant was asked to remain still and momentarily hold
his/her breath twice, each time for 20 to 30 seconds, in order
to get good quality pictures. Participants’ CAC scores were
reported as average CAC Agatston scores. Vessel-specific
CAC scores were calculated in 6,540 MESA participants
(96%). Of those, 6,479MESA participants with coronary cal-
cium CT scans at baseline and vessel-specific CAC distribu-
tion (left main, left anterior descending, left circumflex, and
right) were screened. Included in the final study cohort were
4,917 participants, after exclusion of 1562 participants who
were taking lipid-lowering medication as well as diabetics
and those who lacked measurements of dyslipidemia and/or
CAC. Individuals with triglycerides > 500 were not specifi-
cally excluded from the analysis. However, in those cases it is
usually not possible to calculate LDL-c if using the Friedewald
formula, and patients without LDL-c values would have been
excluded from our analysis.
Cardiovascular risk factors were measured or collected,
and included height, weight, and waist circumference, medi-
cal history including presence of diabetes (using the 2003
American Diabetes Association criteria), hypertension (de-
fined as systolic blood pressure > 139mmHg at baseline visit,
or diastolic blood pressure > 89mm Hg, or by a history of
physician diagnosed hypertension and taking a medication
for hypertension), and assessment of personal habits such as
alcohol and tobacco use [9–11].
2.2. Exposure Variables. The following cardiovascular risk
factors were collected at MESA field centers: height, weight,
waist circumference, alcohol and tobacco use, family history
of heart attack, CAC score, diabetes, and hypertension (sys-
tolic blood pressure ≥ 140mmHg at baseline visit, diastolic
blood pressure ≥ 90mmHg, or a history of taking an anti-
hypertensive medication). Age and race/ethnicity were self-
reported. Lipids, including total and high-density lipoprotein
cholesterol, triglycerides, inflammatorymarkers, and glucose
levels, were measured from fasting plasma samples in a
central laboratory (University of Vermont, Burlington, VT).
Venous blood samples were collected after a 12 h fast by
certified technicians using standardized venipuncture proce-
dures. Samples were then centrifuged at 2000𝑔 for 15min at
4∘C within 30min of collection. EDTA plasma samples were
aliquoted on ice, stored at −70∘C, and then shipped on dry
ice to the MESA central laboratory at University of Vermont
[12].
2.3. Dyslipidemia. Table 1 identifies the various HDL-c, LDL-
c, and triglyceride categories defining the six mutually exclu-
sive dyslipidemias, including normolipidemia as a reference
group.
We created these dyslipidemia groups using criteria
based on current National Cholesterol Education Program
(NCEP)/Adult Treatment Panel- (ATP-) III guidelines that
define LDL-C, HDL-C, and triglyceride thresholds as abnor-
mal [13].
Participants were classified based on the most severe dys-
lipidemia. For example, someone would be classified in the
only MetS if the person had low HDL-c and elevated triglyc-
erides; the person would not be in the low HDL-c group. To
define the subtype of dyslipidemia appropriately, we had to
exclude diabetes and lipid-lowering therapy from this analy-
sis. Diabetes is considered a coronary heart disease risk equiv-
alent and there is a strong independent relationship of dia-
beteswith lowHDL-c, elevated triglycerides, andCACextent.
Participants receiving lipid-lowering therapy were excluded
because lipid lowering has a substantial impact on all lipid
parameters aswell as onCAC. Fasting triglyceridesweremea-
sured in plasma using a glycerol blanked enzymatic method
developed by Trig/GB (Roche Diagnostics, Indianapolis,
Indiana). Cholesterol and HDL-c were measured in plasma
on the Hitachi 911 using a cholesterol esterase, cholesterol
oxidase reaction (Chol R1, Roche Diagnostics). For triglyc-
eride levels < 400mg/dL, the LDL-c was calculated using the
Friedewald formula; otherwise nuclear magnetic resonance
spectroscopy was used for triglycerides > 400mg/dl [9, 14].
Serum glucose was measured by rate reflectance spectropho-
tometry using thin film adaptation of the glucose oxidase
method on the Vitros analyzer (Johnson & Johnson Clinical
Diagnostics Inc., Rochester, NY). The laboratory analytical
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Table 1: Lipid categories defined by HDL, LDL, and triglyceride levels.
Dyslipidemia category HDL (mg/dL) LDL-c (mg/dL) Triglycerides (mg/dL)
Normolipidemia >40 men <160 <150
>50 women
Combined hyperlipidemia No cutoff ≥160 ≥150
Hypercholesterolemia No cutoff ≥160 <150
Dyslipidemia compatible with metabolic syndrome (MetS) ≤40 men <160 ≥150
≤50 women
Low HDL-c ≤40 men <160 <150
≤50 women
Hypertriglyceridemia >40 men <160 ≥150
>50 women
CVwas 1.1%. Insulin was determined by a radioimmunoassay
method using the Linco Human Insulin Specific RIA Kit
(Linco Research Inc., St. Charles, MO). The laboratory
analytical CVwas 4.9%. CRPwasmeasured in the Laboratory
for Clinical Biochemistry Research at University of Vermont
(Burlington, VT). CRP was determined using the BNII
nephelometer (N High-Sensitivity CRP and N Antiserum to
Human Fibrinogen; Dade Behring Inc., Deerfield, IL) [12].
2.4. Coronary Artery Calcium (CAC) Extent. Electron-beam
computed tomography (EBT) or multidetector row helical
computed tomography (MDCT) was used to measure CAC,
defined by a minimum of 130 Hounsfield units [10]. The
effective dose of radiation forCAC scoringwas approximately
1mSv [11]. The protocol and interpretation of CAC scans
in the MESA study have been reported previously [10].
Interobserver and intraobserver agreement were high [15].
The Agatston scoring method quantified baseline CAC [16],
and scores were adjusted with a standard biweekly phantom
scan to ensure equivalence among sites [15].
Extent of CAC was analyzed according to the number of
main coronary arteries (left main, left anterior descending,
left circumflex, and right) with calcification ranging from 0
to 4. Multivessel CAC was defined as involvement of at least
2 coronary arteries. This included three-vessel CAC, which
was defined as involvement of the left main or left anterior
descending coronary artery in addition to CAC in the left
circumflex and the right coronary arteries. Single vessel CAC
was classified as a distinct entity apart from no CAC and
from multivessel disease. Our statistical analysis focused
on the relationship between dyslipidemias and specifically
multivessel disease, as relationships between dyslipidemias
and CAC score in general have previously been described [6].
2.5. Statistical Analysis. A cross-sectional sample of partici-
pants from the MESA cohort was classified into 6 mutually
exclusive dyslipidemia categories (including “normal” as
reference group) based on their levels of LDL-c, HDL-c, and
triglycerides (Table 1). Differences in baseline demographic
and cardiac risk factor data (age, race/ethnicity, gender, clin-
ical site, education, history of hypertension, current smoking
status, alcohol use, waist circumference, fasting glucose,
fasting insulin, CRP, and creatinine)were evaluated across the
6 lipid categories, using the Chi-Square test for categorical
variables and ANOVA for continuous numerical variables.
The latter were reported asmean/standard deviation, with the
exception of skewed variables including CAC score, serum
insulin, CRP, and triglyceride levels, which were reported as
median/interquartile range. Multivariate Poisson regression
analysis was performed to assess the relationship between
multivessel CAC and the type of dyslipidemia (including
normal).This was performed both unadjusting and adjusting
for the aforementioned demographic and cardiac risk factor
data, including the total phantom-adjusted coronary artery
calcium (CAC) score. We chose widely accepted parameters
associated with cardiovascular risk that were also available in
theMESAdatabase. Finalmodel was adjusted for age, gender,
race, high-school education, smoking, hypertension, waist
circumference, serum glucose level, serum insulin, serum
CRP level, and Agatston’s calcium score. All variables were
adjusted simultaneously. The model based on the chosen
variables reflects the well-recognized risk factors associated
with CAC score. All the current variables in our final model
are literature-derived risk factors. We performed the forward
and backward selection to determine the composition of
variables for a good model fit and there was no difference
with either method. In addition, the 𝑝 value for interaction
between different variables such as gender, race/ethnicity, and
CRP and lipid variables was not significant for common or
internal CIMT or prevalent CAC in the previously published
MESA analysis by Paramsothy et al. [6]. A two-sided 𝑝 value
< 0.05 was considered to be significant. Data were analyzed
using SAS version 9.3 (SAS Institute, Cary, NC).
3. Results
3.1. Baseline Characteristics. The baseline characteristics of
the study cohort are shown in Table 2.
The majority of the cohort consisted of white (39%) and
female (53%) participants, with an average age of 61.6 years.
Most participants completed at least a high-school level of
education (83%) and currently used alcohol (58%). Only 14%
of participants were current smokers. Approximately 39% of
the cohort had a history of hypertension, and 53% of the
cohort had one of the five types of dyslipidemia.
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Figure 1:Number of coronary vesselswith calcification as a function
of lipid profiles. The between-group differences in the number of
affected vessels with CAC, showing significant between-group dif-
ferences (𝑝 < 0.001). NL = normolipidemia, Combined = combined
hyperlipidemia, HC = hypercholesterolemia, MetS = dyslipidemia
compatible withmetabolic syndrome, HTG= hypertriglyceridemia,
and CAC = coronary artery calcification.
Table 3: Unadjusted prevalence ratio of multivessel CAC as a func-
tion of lipid groups.
Lipid group PR (95% CI)
Normolipidemia Ref group
Combined hyperlipidemia∗ 1.37 (1.04–1.82)
Hypercholesterolemia∗ 1.33 (1.08–1.64)
Metabolic syndrome dyslipidemia∗ 1.33 (1.14–1.55)
Low HDL-c 1.12 (0.96–1.31)
Hypertriglyceridemia 1.00 (0.79–1.26)
∗Statistically significant at 𝑝 < 0.05.
3.2. Dyslipidemia. The low HDL-c dyslipidemia group was
the most common type of dyslipidemia, followed by the
MetS group. The latter had the largest waist circumference
(Table 2).
3.3. CAC Findings. A comparison was performed using Chi-
Square test between the lipid groups and the number of
affected vessels withCAC, showingsignificant between-group
differences (𝑝 < 0.001, Figure 1).
The normolipidemia group had the highest percentage of
individuals with zero affected vessels (60%), whereas the
combined hyperlipidemia group had the highest percentage
of thosewith three- and four-vessel calcification (16% and 5%,
resp.).
Unadjusted univariate Poisson regression analysis show-
ed that combined hyperlipidemia, simple hypercholestero-
lemia, and dyslipidemia of metabolic syndrome had a statis-
tically significant likelihood of having a multivessel CAC as
compared to the normolipidemia reference group (Table 3).
By contrast, there was no statistically significant dif-
ference between the low HDL-c, hypertriglyceridemia, and
normolipidemia groups in the prevalence of multivessel CAC
in the unadjusted model. Subsequent multivariate Poisson
regression analysis adjusting for the demographic and cardiac
risk factors, including Agatston calcium score, showed that
the same lipid groups (combined hyperlipidemia, simple
hypercholesterolemia, and dyslipidemia of metabolic syn-
drome) and themultivessel CACmaintained statistical signif-
icance in the model, compared to the normolipidemia refer-
ence group (Table 4). Interestingly, the previously nonsignifi-
cant HDL have become significant in the adjusted model.
Furthermore, higher Agatston calcium score, age, male gen-
der, Asian race, currently smoking, hypertension, and waist
circumference were all significantly associated withmultives-
sel disease. The other demographic and cardiac risk factors
previously mentioned were not found to have a significant
relationship with multivessel disease.
4. Discussion
Previous literature has shown that different types of dys-
lipidemia have varying association with CAC scores [2, 3,
6, 17]; however, our study elucidates a relationship between
the different dyslipidemia types and the extent of coronary
artery disease, defined as the rate of multivessel CAC. We
focus on whether or not the heterogeneities of baseline sub-
clinical atherosclerotic extent have any relationship with
dyslipidemia type and, if so, which dyslipidemia is associated
with increased rates of multivessel CAC. As expected, the
majority of the normolipidemia group had no CAC-affected
vessels. In comparison, all dyslipidemia groups except for
the hypertriglyceridemia were associated with higher rates of
multivessel CAC. With further adjustment for demographic
and cardiac risk factors, the same dyslipidemia groups were
still associated with multivessel CAC, even after controlling
for the total CAC score. An earlier study by Paramsothy et
al. showed that, of 4,795 MESA participants, without known
clinical cardiovascular disease, those with combined hyper-
lipidemia, hypercholesterolemia, and MetS had increased
relative risk for prevalent CAC [6] compared with normolipi-
demia participants when adjusting for demographic and
CVD risk factors.
Similar to Paramsothy et al., we found that isolated hyper-
triglyceridemiawas not associatedwithCACextent [6].These
findings suggest that an isolated elevation in triglyceride
levels may not be a pathologic risk factor for subclinical
atherosclerosis, althoughhypertriglyceridemiamay still be an
important factor in cardiovascular disease. The hypertriglyc-
eridemia group in this study also had a relatively high HDL-
c of 53.6mg/DL, which may have inversely affected overall
CAC prevalence [6].
In contrast to the Paramsothy study where no significant
association was found between low HDL-c and prevalent
CAC, we found an association between low HDL-c and
increased extent of CAC.The prevalence of lowHDL-c group
and adjusted risk factors were identical in both studies. In
their study of 6093 participants, Allison and Wright showed
that the individuals with an HDL-c level < 40mg/dl had
significantly higher calcium scores while increases in HDL-
c were associated with a significant reduction in risk for
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Table 4: Adjusted prevalence ratio of multivessel CAC as a function of lipid groups.
Adjusted PR (95% CI)
Lipid group
Normolipidemia Ref group
Combined hyperlipidemia∗ 1.41 (1.06–1.87)
Hypercholesterolemia∗ 1.55 (1.26–1.92)
Metabolic syndrome dyslipidemia∗ 1.28 (1.09–1.51)
Low HD-c∗ 1.20 (1.02–1.40)
Hypertriglyceridemia 1.05 (0.83–1.33)
Age (years)∗ 1.05 (1.05–1.06)
Male sex∗ 1.71 (1.49–1.96)
Race
White Ref group
Asian∗ 1.23 (1.04–1.45)
Black 1.11 (0.88–1.39)
Hispanic 0.89 (0.74–1.07)
High school education 1.05 (0.89–1.23)
Current smoker∗ 1.32 (1.12–1.55)
Hypertension∗ 1.19 (1.05–1.34)
Waist circumference (cm)∗ 1.01 (1.0004–1.010757)
Serum glucose level (mg/dL) 0.99 (0.99–1.00)
Serum insulin level (mu/L) 1.00 (0.99–1.01)
Serum CRP level (mg/L) 1.00 (0.99–1.01)
Serum creatine level (mg/dL) 0.96 (0.74–1.24)
Agatston’s calcium score∗ 1.00 (1.0004–1.0005)
Final model adjusting for age, gender, race, high school education, smoking, hypertension, waist circumference, serum glucose level, serum insulin, serum
CRP level, and Agatston’s calcium score. All variables are adjusted simultaneously. ∗Significant at 𝑝 < 0.01.
the presence of any calcified plaque. Multivariate logistic re-
gression revealed that HDL-c is predictive of calcified plaque
development independent of LDL-c. However, sensitivity
and positive predictive values for HDL-c were low [18].
Furthermore, Noda et al. studied two hundred and eighty-
nine consecutive patients who underwent 64-slice multide-
tector CT for suspected coronary artery disease. They found
that HDL-c cholesterol levels were more accurate for diag-
nosing the presence of high-risk coronary plaque with areas
under receiver operating curve (AUC) of 0.840 in patients
with CCS 0, than with AUC of 0.633 in those with CCS 1 to
10, 0.605 in those with CCS 11 to 100, 0.591 in those with CCS
101 to 400, and 0.571 in those with CCS > 400 [19].Therefore,
in participants with lower CAC score, low HDL-c may have
more influence on the extent of CAC than those with higher
calcium score. This may explain the significance of HDL-c
levels found in our study, since, unlike Paramsothy et al., we
controlled for CAC score and focused on the extent of CAC.
Combined hyperlipidemia, simple hypercholesterolemia,
and participants withMetS had significantly increased risk of
multivessel involvement of the coronary arteries in patients
with subclinical CAD [20]. This is in line with Paramsothy et
al.’s findings where the same dyslipidemia groupswere associ-
atedwith prevalent CAC.Given these findings, elevated LDL-
c seems to be the principal determinant of CAC prevalence
and its extent, with high TG levels having less influence [6, 17,
20, 21]. Of notice, in the multivariate analysis, the confidence
interval of the combined dyslipidemia group is rather wide
because the numbers of participants with this disorder are
relatively small, 172 (3.5%), influencing the precision of the
population estimate.
Atherogenic dyslipidemia is largely underdiagnosed and
undertreated in clinical practice per the findings of Fruchart
et al. in the Residual Risk Reduction Initiative (R3i). These
are prevalent in patients with type 2 diabetes, metabolic
syndrome, and/or established CVD. Especially inMetS, these
patients commonly had elevated ApoB levels, smaller LDL
particle size, and elevated ApoCIII levels and as such meta-
bolic syndrome is associated with residual CVD risk [22].
Gender may also contribute to CAC extent, as we found
CAC extent was significantly increased among men. Male
gender is a recognized independent risk factor for coronary
heart disease by the Framingham Risk Score. In addition,
in their study of 6814 participants, McClelland et al. found
that men had greater calcium levels than women [15]. The
same study showed that calcium amount and prevalence were
steadily higher with increasing age and in Whites, whereas
Asians had the highest ratio of multivessel CAC in our study.
Coronary artery calcium, a known marker of coronary
atherosclerotic plaque, has been consistently associated with
cardiovascular morbidity and mortality [2, 15, 17, 23, 24].The
clinical significance of the demonstrated association between
dyslipidemia types and the extent of CAC, controlling for
CAC score, remains unclear.
Journal of Lipids 7
Although the absence of CAC is not reassuring in symp-
tomatic patients, the CAC score may be associated with myo-
cardial perfusion defects in asymptomatic patients. Studies
have shown that CAC burden and extent predict future
coronary revascularization procedures [24]. As Budoff et al.
first demonstrated, both the number of calcified vessels and
general CAC prevalence are independently associated with
increased likelihood of significant angiographic disease [25].
Moreover, CAC prevalence, adjusting for CAC score, was
predictive of the mode of revascularization. Independent
predictors of coronary artery bypass graft versus percuta-
neous coronary intervention included three- or four-vessel
CAC, higher CAC burden, and involvement of the left main
coronary artery.
The significant association between dyslipidemia types,
except hypertriglyceridemia, and the extent of CAC may
promptmore aggressive treatment and prevention of elevated
LDL-c, low HDL-c, combined hyperlipidemia, and MetS.
Simple hypercholesterolemia may have the greatest impact in
determining the severity of atherosclerotic disease, especially
in those with diabetes and taking lipid-loweringmedications.
As others have shown, LDL-c is the dominant lipid determi-
nant of atherosclerotic disease [6, 17].
As the MESA study gathered data from a large, multieth-
nic population, the results may be widely generalizable. The
imaging and laboratory procedures were standardized at a
common institution. Our study also has several limitations.
Although we attempted to adjust for all possible confounding
factors in our model, the residual confounding by unevalu-
ated factors cannot be completely ruled out. As we examined
cross-sectional associations, the possibility of temporal and
selection biases may exist. Participants on statin therapy
and with diabetes were excluded because these factors could
potentially misclassify the lipid categories and confound the
relationship between dyslipidemia and CAC. We used the
term dyslipidemia compatible with metabolic syndrome in-
stead of dyslipidemia of metabolic syndrome. To define this
category, we did not factor in obesity or blood pressure to
isolate the impact of dyslipidemia on the extent of subclinical
atherosclerosis.
The results of this study further elucidate the role of CAC
in cardiovascular disease. Clinicians already use the CAC
score to predict future cardiovascular morbidity and mortal-
ity in asymptomatic patients with moderate risk factors. Cal-
lister et al. [26] showed that CAC scoring might help assess
the effects of statin therapy. Budoff et al. illustrated a relation-
ship between coronary calcium extent and CABG [25]. Rec-
ognizing the extent of coronary artery calcium may provide
additional information beyond whether or not atheroscle-
rotic disease is present.The association of dyslipidemias with
CAC extent is further evidence in support of the importance
of dyslipidemia, especially simple hypercholesterolemia, as a
target for therapy.
The association between multivessel coronary artery dis-
ease and the cardiovascular risk factors, including dyslipi-
demia, had been widely studied in patients with documented
clinical CVD, using invasive coronary angiography [27, 28].
Our study is novel to address this relationship, assessed by
cardiac computed tomography, in a large multiethnic cohort
free of clinical CVDs at baseline. We believe the underlying
mechanisms of these associations should be relevant to
disease prevention and require further investigation. Fur-
thermore, the current findings may explain the difference
when comparing the results of different studies. For instance,
in patients with low HDL-c, although the CVD risk is
high independently of other cardiovascular risk factors, the
clinical trials have shown lack of improvement in the car-
diovascular outcome when using drug therapies to boost the
level of HDL-c. Our observation highlights the fact that the
relative impact of low HDL-c, and potentially the targeting
pharmacotherapy, on CAD extent may vary depending on
the population selected, low versus high calcium score.
Similarly, CVD outcome studies with triglyceride-lowering
agents have produced inconsistent results, meaning that no
convincing evidence is available that lowering triglycerides by
any approach can reduce mortality. The association between
plasma TG levels (both fasting and nonfasting) and CV risk
is often attenuated once adjusting for other lipid parameters.
However, it is worthy to notice the lack of association between
high TG level and CAC extent existing in our study even
prior to adjusting for other lipid parameters. A number
of studies have found that the association between plasma
TG levels (both fasting and nonfasting) and CV risk is
often attenuated once adjusting for other lipid parameters,
including HDL-c and non-HDL-c. An analysis conducted
by the Emerging Risk Factors Collaboration demonstrated
that there was a significant and stepwise association between
fasting and nonfasting TG levels and CVD risk. However,
this association was no longer significant after adjustment for
HDL-c and non-HDL-c [29]. Elevated TG levels are closely
associatedwith higher levels of non-HDL-c and apoB and low
levels of HDL-c, and this may explain why this association
is weakened after adjustment for these parameters. This is
inherent in the study design since we classified the study
cohort into 6 mutually exclusive dyslipidemia categories.
Further research is needed in examining coronary artery
calcium extent, not simply the score, as a potential tool in
prognosticating, treating, and perhaps preventing subclinical
atherosclerosis in otherwise low-risk populations. Other
lipid parameters such as non-HDL-c and lipoprotein(a)
(Lp(a)) have been proposed as independent risk factors for
coronary heart disease and their impact on the extent of
multivessel CAC needs to be explored further. A previous
study using the MESA population showed that non-HDL-c
is independently associated with increased CAC in patient
populations without CAC at baseline and especially non-
HDL-c > 190 is associated with a significant progression of
CAC [30]. Nonetheless, we have identified the 5 major dys-
lipidemia groups in our analysis based on current National
Cholesterol Education Program (NCEP)/Adult Treatment
Panel- (ATP-) III guidelines that define LDL-C, HDL-C, and
triglyceride thresholds as abnormal. These groups account
for the complexity of having more than 1 abnormal lipid
parameter in the individual patients. It is challenging to create
another mutually exclusive group by using non-HDL-c cutoff
because this parameter encompasses all of the circulating
atherogenic lipoproteins, including LDL-c. Furthermore, the
aforementioned study included participants with diabetes
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and lipid-lowering medications, whom we excluded in the
current analysis, to avoid the effect of these 2 factors on lipid
parameters and CAC.
Genetic studies and multiple epidemiologic studies have
identified Lp(a) as a risk factor for atherosclerotic diseases
such as coronary heart disease and stroke [31]. In a previous
study of 410 outpatients, Jug et al. showed that LP(a) is an
independent predictor of coronary calcium (odds ratio 7.81,
95% confidence interval 1.41 to 43.5) [32]. In another study
by Cho et al., participants with Lp(a) level ≥ 50mg/dL had an
odds ratio of 1.333 (95% CI 1.027–1.730) for CAC progression
compared to those with Lp(a) < 50mg/dL after adjusting for
confounding factors [33]. Future investigations testing the
association between the Lp(a) and CAC extent in popula-
tion free of CVD at baseline are warranted. In addition, a
published study of MESA showed that the measures of CAC
burden and distribution each are independently predicting
need for percutaneous coronary intervention versus CABG
over an 8.5-year follow-up [2]. The new ACC/AHA 2013
guidelines support intensifying statin therapy when the CAC
score is ≥75th percentile for age, gender, and ethnicity/race or
when the calcium score is ≥300 Agatston units [34].Whether
adding the extent of CAC, single versus multivessel CAC, to
the absolute calcium score poses any incremental therapeutic
value needs to be tested in a large population-based cohort.
5. Conclusion
In a population-based cohort, the extent of multivessel CAC
was associated with different dyslipidemia types except for
hypertriglyceridemia. The results were still significant even
after controlling for CAC score. Future research should focus
on themechanistic understanding of this relationship for dis-
ease prevention and investigate the association between other
promising lipid parameters and CAC extent in asymptomatic
adults with subclinical atherosclerosis.
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